ArticleDiscover nano2026
Antiviral activity of green synthesized selenium nanoparticles alone and in combination with chitosan against SARS-CoV-2.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Gold Nanoparticles for Antiviral Applications: Design Principles, Surface Engineering, and Mechanistic Insights.Pharmaceutics · 2026Review
- Chitosan Derivatives: Challenges and Opportunities in the Green and Sustainable Transition Era.Molecules (Basel, Switzerland) · 2026Review
- Optimization of probiotic-mediated selenium nanoparticles for superior antibacterial action against methicillin-resistant Staphylococcus aureus.Discover nano · 2026Article
- Nanomedicine against antimicrobial resistance: mechanistic insights and next-generation therapeutic potential.Frontiers in chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanobiotechnology is increasingly used to control viral diseases such as COVID-19, with selenium nanoparticles (SeNPs) and their composite with chitosan (CS) gaining attention for their broad bioactivity and potential as antiviral agents, but challenges related to synthesis methods, cytotoxicity, and mechanistic understanding remain. In this study, we report a novel, green biosynthesis of SeNPs using Limosilactobacillus fermentum, followed by functionalization with chitosan to produce Se/CS nanocomposites with enhanced antiviral performance against SARS-CoV-2. L. fermentum was used to biosynthesize SeNPs, providing a rapid, safe, and environmentally friendly approach. The production process was optimized by testing different parameters such as concentrations of Na
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.